Clearside Biomedical Inc. (Nasdaq: CLSD) reported positive results from a Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis. Shares of the biopharmaceutical leaped $2.51 to close at $10.33.
